Ocuphire Pharma reports FY 2023 net loss of $10M; advances APX3330 Phase 3 and RYZUMVI launch

Opus Genetics, Inc.

Cash $50.5M at Dec 31, 2023; management expects to fund operations into mid-2025.
FY 2023 revenue $19.0M (incl. $10M Viatris milestone) vs $39.9M in 2022; net loss $10.0M ($0.46/share) vs net income $17.9M in 2022.
APX3330 SPA submitted for Phase 3 registrational trial in diabetic retinopathy; FDA agreed on primary endpoint.
RYZUMVI (phentolamine) approved Sep 2023; launch expected H1 2024; Viatris to fund further development for presbyopia and post-refractive surgery.
Leadership changes: George Magrath CEO (Nov 2023), new CFO and CSDO appointed Feb 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Opus Genetics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $1.7 million and $19.0 million for the fourth quarter and year ended December 31, 2023, respectively.

Period: the fourth quarter and full year ended December 31, 2023
Revenue: $1.7 million and $19.0 million for the fourth quarter and year ended December 31, 2023, respectively
Result: reported results

Exact text from the filing

On March 8, 2024, Ocuphire Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

31 earnings releases filed in the last 30 days. Browse all earnings releases →

Opus Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-012128

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.